瑞和生醫股份有限公司
Update：2026/10/21
Industries
Main Industry
Biotechnology
Main Product/Service
Provides an integrated functional drug sensitivity testing service that combines patient-derived tumor spheroids (PDTS), automated high-throughput screening (HTS), and an AI-powered intelligent prediction engine. By integrating the analysis of the tumor microenvironment, biological characteristics, genomics, and drug sensitivity data, it generates personalized drug sensitivity testing reports to assist in the clinical evaluation of anticancer drug efficacy, drug resistance markers, and molecular target activity, providing a valuable reference for precision medical decision-making.
(The content above was translated by AI.)
(The content above was translated by AI.)
Founded Year
2024
Unified Business No.
98641704
Status
Active
Number of Employees
8
Total Paid-in
Capital
25,300,000 (NT$)
Location of Company
Taiwan
, Taipei City
Company names, registration status, legal representatives, founding years, paid-in capital, registered addresses, and other details are sourced from business registration records maintained by Taiwan’s Administration of Commerce, Ministry of Economic Affairs. Exit status includes Emerging Stock Board listings, M&A, and IPOs. Information on overseas expansion is self-reported by startups.
Note 1: FINDIT compiles company information from public and other sources for reference and does not serve as a point of contact for the companies listed.
Note 2: Some company profiles and product/service descriptions are translated using AI and provided for reference only. In case of discrepancies or ambiguity, the original text prevails.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
瑞和生醫股份有限公司 (MatchCure Inc.) is a startup company driven by the dual cores of cutting-edge biomedical technology and data science, founded with an original intention stemming from a profound understanding of the limitations of current tumor diagnosis and treatment. Traditional pathology and genomic testing mostly provide static molecular information, making it difficult to directly predict the actual functional dynamic response of tumors to chemotherapy or targeted drugs, which leaves clinical treatment still highly dependent on experience and trial-and-error strategies. The company utilizes patient-derived tumor spheroids (Patient-Derived Tumor Spheroid, PDTS) and automated high-throughput screening (High-Throughput Screening, HTS) as its core platforms to establish quantifiable and reproducible in vitro tumor drug efficacy evaluation technologies.
瑞和生醫 has taken the lead in introducing medical-grade PDTS technology into companion animal oncology (Pet Oncology) clinical decision support services, responding to the demand for precision treatment in the pet market, which has a high proportion of out-of-pocket expenses, and assisting veterinarians in providing more evidence-based treatment options for canine and feline cancer patients. This model not only improves the quality of life and survival rates of pet cancer patients, but also establishes a high-barrier source of early revenue, while simultaneously accumulating high-value real-world drug sensitivity data and clinical response data.
In terms of development strategy, 瑞和生醫 structurally integrates pet clinical drug sensitivity data with multi-omics information to further develop AI-driven drug efficacy prediction and decision-making models, providing B2B services such as preclinical evaluation, toxicity prediction, and drug repurposing (Drug Repurposing) to pharmaceutical research and development companies. Through the cross-species linkage of comparative oncology (Comparative Oncology), the company will also gradually advance into application scenarios of human personalized oncology.
(The content above was translated by AI.)
瑞和生醫 has taken the lead in introducing medical-grade PDTS technology into companion animal oncology (Pet Oncology) clinical decision support services, responding to the demand for precision treatment in the pet market, which has a high proportion of out-of-pocket expenses, and assisting veterinarians in providing more evidence-based treatment options for canine and feline cancer patients. This model not only improves the quality of life and survival rates of pet cancer patients, but also establishes a high-barrier source of early revenue, while simultaneously accumulating high-value real-world drug sensitivity data and clinical response data.
In terms of development strategy, 瑞和生醫 structurally integrates pet clinical drug sensitivity data with multi-omics information to further develop AI-driven drug efficacy prediction and decision-making models, providing B2B services such as preclinical evaluation, toxicity prediction, and drug repurposing (Drug Repurposing) to pharmaceutical research and development companies. Through the cross-species linkage of comparative oncology (Comparative Oncology), the company will also gradually advance into application scenarios of human personalized oncology.
(The content above was translated by AI.)
